Analysis of Microplastics in Human Feces Reveals a Correlation between Fecal Microplastics and Inflammatory Bowel Disease Status

2021 ◽  
Author(s):  
Zehua Yan ◽  
Yafei Liu ◽  
Ting Zhang ◽  
Faming Zhang ◽  
Hongqiang Ren ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Disease Status ◽  
Human Feces ◽  
Inflammatory Bowel

Relations between disease status and body composition in pediatric inflammatory bowel disease

2020 ◽  
Vol 179 (10) ◽  
pp. 1499-1505
Author(s):  
Saurabh Talathi ◽  
Pooja Nagaraj ◽  
Traci Jester ◽  
Jeanine Maclin ◽  
Taylor Knight ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Body Composition ◽  
Bowel Disease ◽  
Disease Status ◽  
Pediatric Inflammatory Bowel Disease ◽  
Inflammatory Bowel

967 Cervical Dysplasia and Inflammatory Bowel Disease: No Effect of Disease Status or Immunosuppressants On Analysis of 2,199 Smear Records

2008 ◽  
Vol 134 (4) ◽  
pp. A-143-A-144 ◽  
Author(s):  
Charles W. Lees ◽  
Julia Critchley ◽  
Nellie M. Chee ◽  
Alan G. Shand ◽  
Ian D. Arnott ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Cervical Dysplasia ◽  
Disease Status ◽  
Inflammatory Bowel

Development of quality measures for use of self-injectable biologic therapy in inflammatory bowel disease: An integrated specialty pharmacy initiative

2019 ◽  
Vol 76 (17) ◽  
pp. 1296-1304 ◽  
Author(s):  
Nisha B Shah ◽  
Jacob A Jolly ◽  
Sara N Horst ◽  
Megan Peter ◽  
Heather Limper ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Health System ◽  
Bowel Disease ◽  
Biologic Therapy ◽  
Clinical Care ◽  
Disease Status ◽  
Quality Measures ◽  
Pharmacy Benefit Manager ◽  
Inflammatory Bowel ◽  
Specialty Pharmacy

Abstract Purpose The development of a tool to measure medication safety, therapeutic efficacy, and other quality outcomes in patients receiving self-injectable biologic therapy for the management of inflammatory bowel disease (IBD) at a health-system specialty pharmacy is described. Summary Through a collaborative initiative by pharmacists, gastro-enterologists, and representatives of a pharmacy benefit manager and a pharmaceutical company, a set of clinical and specialty pharmacy quality measures was developed. The clinical measures are intended for use in assessing patient safety, disease status, treatment efficacy, and healthcare resource utilization during 3 assessments (pre-treatment, on-treatment, and longitudinal). The specialty pharmacy measures can be used to assess medication adherence, medication persistence, specialty pharmacy accreditation, and patient satisfaction. The proposed quality measures provide a foundation for evaluating the quality of IBD care and improving patient outcomes within a health-system specialty pharmacy. Future efforts to validate and implement the tool in clinical practice are planned. Conclusion The proposed quality measures provide a foundation for future inquiry regarding the appropriateness and feasibility of integrating the measures into clinical care. Further work is needed to implement and validate these quality measures and determine their impact in optimizing health outcomes.

Exosomes in Inflammatory Bowel Disease: What Have We Learned So Far?

2020 ◽  
Vol 21 (14) ◽  
pp. 1448-1455
Author(s):  
Haichao Wang ◽  
Chen Ye ◽  
Yaling Wu ◽  
Pengyu Yang ◽  
Chunqiu Chen ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Immunosuppressive Agents ◽  
Disease Status ◽  
Lipid Vesicles ◽  
Chronic Inflammatory Disease ◽  
Microbial Dysbiosis ◽  
Therapeutic Benefits ◽  
Inflammatory Bowel ◽  
Maintenance Of Remission

Inflammatory bowel disease (IBD) is an immune-mediated chronic inflammatory disease. Although the etiology is uncertain, there is marked disbalance of mucosal immune responses in part shaped by genetic susceptibility and intestinal microbial dysbiosis. Suppressing inflammatory activity adequately and maintaining this suppression are the main goals of current therapies. However, corticosteroids are only suitable for therapy of active disease, and the effects of immunosuppressive agents are mainly limited to maintenance of remission. Biologics have become widely available and provide therapeutic benefits to IBD patients. However, only a part of patients benefits from them. Thus, there is an urgent need for the development of new substances in the therapy of IBD. Exosomes are nanosized lipid vesicles identified recently. They are secreted from all living cells and then distributed in various human body fluids. The components, such as microRNAs and functional proteins, secreted by exosomes in different cells have been reported to be involved in the pathogenesis of IBD. Therefore, exosomes have the potential to become appealing particles in treating IBD as a cell-free therapeutic approach as well as biomarkers for diagnosis and monitoring disease status. Further studies are needed to investigate the practicality, safety and desirable effects of exosomes in clinical applications in IBD.

Metabolomic Analysis in Inflammatory Bowel Disease: A Systematic Review

2020 ◽  
Author(s):  
Kate Gallagher ◽  
Alexandra Catesson ◽  
Julian L Griffin ◽  
Elaine Holmes ◽  
Horace R T Williams
Keyword(s):  
Systematic Review ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Disease Status ◽  
Microbial Metabolism ◽  
Microbial Dysbiosis ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Branched Chain ◽  
Secondary Bile Acids

Abstract Background and aims The inflammatory bowel diseases (IBD), Crohn’s disease and ulcerative colitis, are chronic, idiopathic gastrointestinal (GI) diseases. Whilst their precise etiology is unknown, it is thought to involve a complex interaction between genetic predisposition and an abnormal host immune response to environmental exposures, likely microbial. Microbial dysbiosis has frequently been documented in IBD. Metabolomics (the study of small molecular intermediates and end products of metabolism in biological samples) provides a unique opportunity to characterize disease-associated metabolic changes and may be of particular use in quantifying gut microbial metabolism. Numerous metabolomic studies have been undertaken in inflammatory bowel disease populations, identifying consistent alterations in a range of molecules across several biological matrices. This systematic review aims to summarize these findings. Methods A comprehensive, systematic search was carried out using Medline and EMBASE. All studies were reviewed by two authors independently using predefined exclusion criteria. A total of sixty-four relevant papers were quality assessed and included in the review. Results Consistent metabolic perturbations were identified, including increases in levels of branched chain amino acids and lipid classes across stool, serum, plasma and tissue biopsy samples, and reduced levels of microbially modified metabolites in both urine (such as hippurate) and stool (such as secondary bile acids). Conclusions This review provides a summary of metabolomic research in IBD to date, highlighting underlying themes of perturbed gut microbial metabolism and mammalian-microbial co-metabolism associated with disease status.

P115 RELATIONS BETWEEN DISEASE STATUS AND BODY COMPOSITION IN PEDIATRIC INFLAMMATORY BOWEL DISEASE

2020 ◽  
Vol 158 (3) ◽  
pp. S30-S31
Author(s):  
Saurabh Talathi ◽  
Pooja Nagaraj ◽  
Traci Jester ◽  
Jeanine Maclin ◽  
Taylor Knight ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Body Composition ◽  
Bowel Disease ◽  
Disease Status ◽  
Pediatric Inflammatory Bowel Disease ◽  
Inflammatory Bowel

scholarly journals Questionnaire assessment helps the self-management of patients with inflammatory bowel disease during the outbreak of Coronavirus Disease 2019

2020 ◽  
Author(s):  
Meiping Yu ◽  
Zhenghao Ye ◽  
Yu Chen ◽  
Tingting Qin ◽  
Jiguang Kou ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Traffic Control ◽  
Disease Status ◽  
The Self ◽  
Disease Stage ◽  
Self Management ◽  
Significant Difference ◽  
Patient Reported ◽  
Inflammatory Bowel

AbstractBackground and AimsThe outbreak of Coronavirus Disease 2019 (COVID-19) may affect the disease status of patients with inflammatory bowel disease (IBD). This study aimed to assess the disease status of IBD patients in Hubei province by questionnaire online and guide to the self-management of IBD patients during this epidemic.MethodsA questionnaire was designed containing the Harvey-Bradshaw Index (HBI), the Partial Mayo Score (PMS), the short inflammatory bowel disease questionnaire (SIBDQ) and distributed to Hubei IBD patients online within one month of traffic control after the outbreak of COVID-19. This questionnaire also included some questions about patients’ self-report disease conditions and their epidemiological history of COVID-19.ResultsA total of 102 eligible questionnaires were included in the analysis. No patient reported infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in our study. Our result showed that 69.64% of patients with ulcerative colitis (UC) and 80.44% of patients with Crohn’s disease (CD) were in remission. There was not a statistically significant difference in the proportion of the active disease stage between the two types of disease (p=0.103). The majority of patients (85.29%) had a good health-related quality of life (HRQoL) (SIBDQ≥50). The reduction in physical exercise is a risk factor for worsening in conditions (OR=17.593, 95%CI 2.035 to 152.097, p=0.009).ConclusionsThe outbreak of COVID-19 might not have a significant impact on most Hubei IBD patients within one month after the traffic control. The patient’s disease condition could be assessed by our questionnaires. Doctors utilized the information and advised for IBD patients about self-management during the period of COVID-19.

Sign in / Sign up

Export Citation Format

Share Document